Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00834457 | A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe | PHASE2 | COMPLETED | 49 | — | — | Jun 1, 2007 | Jul 1, 2009 | Oct 30, 2014 | 1 | Zimbabwe |
| Arm | Type | Description |
|---|---|---|
| 2A | ACTIVE_COMPARATOR | co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg po(Trizivir)one tablet twice daily(BID)for 96 weeks |
| 2B | ACTIVE_COMPARATOR | co-formulated abacavir 600mg/3TC 300mg orally (as Kivexa) one tablet daily plus fixed dose lopinavir 133.3mg/ritonavir 33.3mg orally (as Aluvia) four tablets daily for 96 weeks |
| Name | Type | Description |
|---|---|---|
| abacavir/3TC/zidovudine | DRUG | continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks |
| abacavir /3TC plus ritonavir boosted lopinavir | DRUG | fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks |
Inclusion Criteria:Completion of at least 96 weeks of treatment with ABC/3TC/ZDV on protocol Step 1. * Currently receiving ABC/3TC/ZDV on Step 1/initial open-label allNRTI phase of study. * Plasma HIV-1 RNA \< 400 copies/mL on the most recent plasma HIV-1 RNA performed within 4 weeks of Step 2 entr...